<?xml version="1.0"?>
<Articles JournalTitle="Iranian Journal of Allergy, Asthma and Immunology">
  <Article>
    <Journal>
      <PublisherName>Tehran University of Medical Sciences</PublisherName>
      <JournalTitle>Iranian Journal of Allergy, Asthma and Immunology</JournalTitle>
      <Issn>1735-1502</Issn>
      <Volume>21</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="epublish">
        <Year>2022</Year>
        <Month>04</Month>
        <Day>11</Day>
      </PubDate>
    </Journal>
    <title locale="en_US">The Effects of Combined Therapeutic Protocol on Allergic Rhinitis Symptoms and Molecular Determinants</title>
    <FirstPage>141</FirstPage>
    <LastPage>150</LastPage>
    <AuthorList>
      <Author>
        <FirstName>Yuanfeng</FirstName>
        <LastName>Shen</LastName>
        <affiliation locale="en_US">Department of Otolaryngology, Traditional Chinese Medical Hospital of Huzhou&#xFF0C;Huzhou&#xFF0C;Zhejiang, China</affiliation>
      </Author>
      <Author>
        <FirstName>Entezar</FirstName>
        <LastName>Mehrabi Nasab</LastName>
        <affiliation locale="en_US">Department of Cardiology, Tehran Heart Center, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Fatemeh</FirstName>
        <LastName>Hassanpour</LastName>
        <affiliation locale="en_US">Faculty of Veterinary Medicine, Urmia University, Urmia, Iran</affiliation>
      </Author>
      <Author>
        <FirstName>Seyyed Shamsadin</FirstName>
        <LastName>Athari</LastName>
        <affiliation locale="en_US">Department of Immunology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran</affiliation>
      </Author>
    </AuthorList>
    <History>
      <PubDate PubStatus="received">
        <Year>2021</Year>
        <Month>09</Month>
        <Day>04</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2021</Year>
        <Month>10</Month>
        <Day>23</Day>
      </PubDate>
    </History>
    <abstract locale="en_US">Current medications to treat allergic rhinitis (AR) include antihistamines, corticosteroids, and anti-leukotrienes. In the present study, we investigated the effects of combination therapy; using these drugs, and evaluates the AR-related markers and parameters in an animal model.
After inducing BALB/c mice AR models, the animals were treated with either pranlukast, loratadine, fluticasone, loratadine + fluticasone, loratadine + pranlukast, fluticasone + pranlukast, or loratadine + fluticasone + pranlukast. Clinical symptoms, Immunoglobulin (Ig)G1, ovalbumin (OVA)-specific and total IgE, leukotriene (LT)B4, LTC4, histamine, thymic stromal lymphopoietin (TSLP) serum levels, and interleukin 4 level in the nasal lavage fluid were determined. The expressions of HRH1, CysLT1R, NLR3, Caspase-1, and MUC5a were studied.
Allergic symptoms (nasal rubbing and sneezing), serum Igs (IgG1, total and OVA-specific IgE), eicosanoids (LTB4 and LTC4), histamine, TSLP, and IL-4 as well as gene expressions of MUC5a, Caspase-1, NLR3, HRH1, and CysLT1R were reduced in the animals receiving each of the therapeutic regimens; however, more pronounced effects were seen in the group treated with the triple combined protocol (loratadine + fluticasone + pranlukast).
The combination of the loratadine, fluticasone, and pranlukast can effectively control the symptoms of AR probably via modulating several related mechanisms at early and late phases of allergic responses.</abstract>
    <web_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/view/3347</web_url>
    <pdf_url>https://ijaai.tums.ac.ir/index.php/ijaai/article/download/3347/1826</pdf_url>
  </Article>
</Articles>
